Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. - Wikidata - wikimedia - TriplyDB

Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.

Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.

http://www.wikidata.org/entity/Q36071512

about

Clostridium difficile infection: a review of current and emerging therapies Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance Murine models to study Clostridium difficile infection and transmission Diversity and Evolution in the Genome of Clostridium difficile Fecal microbiota therapy: ready for prime time?Persistent and Recurrent Clostridium difficile Colitis.Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostridium difficile.Fecal microbiota transplantation for the management of Clostridium difficile infection The systemic inflammatory response to Clostridium difficile infection High-throughput analysis of gene essentiality and sporulation in Clostridium difficile Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection.A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection.Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production Association of relapse of Clostridium difficile disease with BI/NAP1/027.Immunogenicity and protective efficacy of Clostridium difficile spore proteins.Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings.Environmental Contamination in Households of Patients with Recurrent Clostridium difficile Infection Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.Genetically diverse Clostridium difficile strains harboring abundant prophages in an estuarine environment.Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.Fidaxomicin: a review of its use in patients with Clostridium difficile infection.Clostridium difficile infection in newly diagnosed pediatric inflammatory bowel disease in the mid-southern United States.Novel therapeutic strategies for Clostridium difficile infections.The search for new sporicidal agents for medical use: where are we?Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection.Healthcare-Associated Clostridium difficile Infections are Sustained by Disease from the Community.Distinguishing Clostridium difficile Recurrence From Reinfection: Independent Validation of Current Recommendations.Long-term microbiota and virome in a Zürich patient after fecal transplantation against Clostridium difficile infection.First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis.Vaccination against Clostridium difficile using toxin fragments: Observations and analysis in animal models Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model.Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection.Risk factors and management of refractory or recurrent clostridium difficile infection in ileal pouch patients.

P2860

Q26750157-1FC36A8F-7241-4ECA-9473-C445065302CE Q26752760-E1220AB3-A273-4444-AD8E-FD548A34AC91 Q26771995-7D931F06-9A57-4228-AC21-E88CD7246CF1 Q26859965-0A9E55C3-CF32-4F37-85E1-BC3550839495 Q28084700-F8CBAA17-05F3-46E1-8E78-F8572168BCAB Q34038951-D6D854B1-50CD-468F-89AC-3DE2A6A1E018 Q34670156-0C3AB667-57F0-4D06-9200-2E57945C1E4E Q35050290-1B017298-5C65-41D9-A933-1B6435AEFD72 Q35083682-C4F58FB0-0283-4FF5-8101-5147B6049C63 Q35124315-FFBFC934-C3A8-4619-BB0A-0AD8A909D3E6 Q35567539-1F6CFAEE-D3FA-4D8E-B66E-E3C18FDE83CA Q35605686-96CC2897-8102-4E59-88A3-98C2B4317C84 Q35677616-7179E231-EC42-4218-8CAE-26AF27E878D7 Q36018079-91B97FE5-4E7E-4E0F-AF5F-15DFD652BB64 Q36111393-0F629BC7-0403-4C9C-8D0E-74777D8ED61F Q36414097-926CE7AC-C116-4C08-906F-78B6BC04C83F Q36630071-E84C2033-ECD8-4595-9005-1D738B02892A Q36726659-3DCD56FE-4A0A-40EB-966B-329687CF590A Q36812229-F2A6FA86-489B-424C-A1A7-2CBDC431D1ED Q36891309-0F5FFF39-AA7D-4DCC-85B0-0FEDB3F5C30B Q37035829-28A80B9F-3909-4E85-9CE5-96D96C1C8A13 Q37263237-78A04D41-0156-48CD-9ADE-E8FA796A97D0 Q37696597-3663D350-4E1A-414A-87AD-A92E208F3F48 Q38153607-F3D8744E-EA8E-4859-83B9-6401E051C55D Q38569836-FE312957-ED71-4316-8790-E868289F26DC Q38632664-7DA53975-390B-4511-8F46-6E9615BA86C8 Q38673389-F3DD86B3-C82C-4D84-869B-8A073BF91EFE Q38904050-73BA4774-6019-4478-BC9E-335F138F5D9B Q39564798-EA16F2A8-F4B9-4B36-8210-63DBFAE89D3C Q40085926-ED49C59F-5DB0-4AA4-9DEB-95E359382BAF Q40106953-B20F8503-7AA3-4532-BA48-14EEA968855C Q40168493-FFC206A3-C124-4315-BBD4-2B1A6249CF76 Q40708125-E070CB4C-DC6C-41F6-A71E-02ED7625E751 Q40837374-7F79CFFC-13F0-41DD-8D0F-F915A9213243 Q40899692-BE0B86FF-CBE4-4418-8BBE-A83B212C0CD7 Q41175414-DD4BF780-1CAC-4CE1-835F-96EA44F6111C Q41194710-E0E3523F-BB76-4BF9-9E05-3087B2F3CD6F Q41272713-C342E0DF-02C4-4C0C-B9E9-4D4FE3ABACB1 Q41419861-0FF6B92E-5ADD-4DCA-A4DF-87A59B4BA357 Q41739117-BC5519D6-34B9-49E2-8DAB-50836EF0271C

P2860

Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.

http://www.wikidata.org/entity/Q36071512

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Relapse versus reinfection: re ...... ith fidaxomicin or vancomycin.

@ast

Relapse versus reinfection: re ...... ith fidaxomicin or vancomycin.

@en

type

label

Relapse versus reinfection: re ...... ith fidaxomicin or vancomycin.

@ast

Relapse versus reinfection: re ...... ith fidaxomicin or vancomycin.

@en

prefLabel

Relapse versus reinfection: re ...... ith fidaxomicin or vancomycin.

@ast

Relapse versus reinfection: re ...... ith fidaxomicin or vancomycin.

@en

P1433

Q36071512-6A3DD17F-75D9-4069-B6D8-16F145F52C5C

P1476

Q36071512-ED4BCF08-0040-47BE-8658-396B995A3766

P2093

Q36071512-358D5125-A5C4-4A4A-8FAE-B7B3783EA8ED

Q36071512-3C2CFE88-DD4F-490B-A5AC-45F0558CE334

Q36071512-8CE33DC9-CD86-466A-B9F8-99E288445A8B

Q36071512-A24CB6CE-A0AB-45D5-AF48-E1B88FC9F033

Q36071512-FE0EE1E3-7B05-4BC5-899D-C20583045916

P2860

Q36071512-02EF6EBE-8E3E-4B23-800E-A08047BCC96E

Q36071512-042D5050-27F1-4ACC-82E8-27DA8A61D90B

Q36071512-1F47FCA9-7F14-460A-B76E-FEA274237F95

Q36071512-2AA9AAAA-EC6B-4418-AC83-E98CE7CE9A7B

Q36071512-2F6530C7-4ED7-42D4-A387-E6BB34F13A7B

Q36071512-4FC07C61-B375-4024-9ED7-D78849BE017E

Q36071512-7D7C89A5-3D18-4D8F-958C-2E17212628D0

Q36071512-825FBCCC-7781-4C7B-84FE-BE595137B5E5

Q36071512-84ACF30E-FF7D-4B7C-824D-4001B27225E3

Q36071512-8ADA7FFF-9ECC-4563-A6E2-26CA98A73134

P304

Q36071512-408AE2FA-E9CC-47FF-8311-6F7464F20B64

P31

Q36071512-E0B79328-E18A-46B2-96BE-F696401D07FC

P356

Q36071512-24B27BE7-0990-4397-8B64-6C309228F5B9

P407

Q36071512-771E0153-06BE-4F64-8100-59282D6267E4

P478

Q36071512-9AA45C6E-F4C9-4B39-83D4-F4531B1A0385

P50

Q36071512-1D6F155F-23B8-47D0-95DD-FD44A3612FD9

P577

Q36071512-2BC3BFEB-4BAA-4B89-9936-9D908BD6E79E

P5875

Q36071512-794E0753-5262-4CB8-A82C-B7DFFC0A9DC1

P698

Q36071512-C8250DFB-7A0C-4FF9-BED5-87B205B23CA7

P921

Q36071512-89832124-DC56-454F-9D69-EAEB6D605FB8

P932

Q36071512-D9D119BA-304B-47A1-968B-7E157A61652C

P356

P1433

Clinical Infectious Diseases

P1476

Relapse versus reinfection: re ...... ith fidaxomicin or vancomycin.

@en

P2093

Diane M Citron

http://www.w3.org/2001/XMLSchema#string

Ellie J C Goldstein

http://www.w3.org/2001/XMLSchema#string

Iris Figueroa

http://www.w3.org/2001/XMLSchema#string

Stuart Johnson

http://www.w3.org/2001/XMLSchema#string

Susan P Sambol

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.

Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.

Fidaxomicin versus vancomycin for Clostridium difficile infection.

Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.

Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.

Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-rep

Relapse versus reinfection with Clostridium difficile.

Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent clostridium difficile-associated diarrhea.

Molecular epidemiology of Clostridium difficile over the course of 10 years in a tertiary care hospital.

Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems.

P304

S104-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIS357

http://www.w3.org/2001/XMLSchema#string

P407

P478

55 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228328995

http://www.w3.org/2001/XMLSchema#string

P698

22752857

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile

P932

3388025

http://www.w3.org/2001/XMLSchema#string